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IL-1 and , which were originally described as 
leukocytic pyrogens (1), are important regula-
tors of the response to tissue damage and infec-
tions and mediate symptoms of fever, fatigue, 
pain, arthritis, and the hepatic acute phase re-
sponses including synthesis of C-reactive protein 
(CRP) and serum amyloid A protein (SAA) (2). 
Although  studies  using  recombinant  IL-1  in 
cancer patients confirmed the causative role of 
IL-1 for many of these symptoms (3), its direct 
investigation in man is hampered by the inability 
to detect IL-1 in biological fluids. cryopyrin-as-
sociated periodic syndromes (CAPS) is a clinical 
disease syndrome resulting from heterozygous 
gain-of-function mutations in NLRP3, the gene 
encoding cryopyrin. These mutations are sup-
posed to promote release of IL-1, thereby pro-
viding an excellent paradigm for studying human 
IL-1 in vivo (4, 5). CAPS patients present with 
a spectrum of autoinflammatory diseases (6–11) 
involving almost all organ systems. NLRP3 mu-
tations result in overactivation of caspase 1, the 
enzyme which cleaves the precursors of IL-1, 
IL-18, and IL-33, members of the IL-1 family of 
cytokines, into their active forms (12). Although 
pro–IL-1 is not a substrate of caspase 1, recent 
studies in mice indicate that secretion of bioac-
tive IL-1 requires functional NLRP3 (13) and 
activated caspase-1 (14). The recombinant IL-1 
receptor antagonist (IL-1Ra) anakinra and the 
IL-1  receptor  type  I  (IL-1RI)  fusion  protein 
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The investigation of interleukin 1 (IL-1) in human inflammatory diseases is hampered by 
the fact that it is virtually undetectable in human plasma. We demonstrate that by admin-
istering the anti–human IL-1 antibody canakinumab (ACZ885) to humans, the resulting 
formation of IL-1–antibody complexes allowed the detection of in vivo–produced IL-1. 
A two-compartment mathematical model was generated that predicted a constitutive 
production rate of 6 ng/d IL-1 in healthy subjects. In contrast, patients with cryopyrin-
associated periodic syndromes (CAPS), a rare monogenetic disease driven by uncontrolled 
caspase-1 activity and IL-1 production, produced a mean of 31 ng/d. Treatment with 
canakinumab not only induced long-lasting complete clinical response but also reduced the 
production rate of IL-1 to normal levels within 8 wk of treatment, suggesting that IL-1 
production in these patients was mainly IL-1 driven. The model further indicated that IL-
1 is the only cytokine driving disease severity and duration of response to canakinumab.  
A correction for natural IL-1 antagonists was not required to fit the data. Together, the 
study allowed new insights into the production and regulation of IL-1 in man. It also 
indicated that CAPS is entirely mediated by IL-1 and that canakinumab treatment re-
stores physiological IL-1 production.
© 2009 Lachmann et al.  This article is distributed under the terms of an Attribu-
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(Fig. 1 C). Sensitive markers for neutrophil (S100A12) and 
monocyte/macrophage activation (S100A8/9) (18) showed a 
rapid decline (Fig. 1 D) along with a normalization of neu-
trophil counts (Fig. 1 F). Levels of soluble IL-1RII in se-
rum were within the normal range and showed no change   
after treatment (Fig. 1 E). Canakinumab induced long-lasting 
complete clinical response; the median time until redosing 
after relapse was 185 d (Table I). Patients were retreated i.v. 
with 1 mg/kg canakinumab, resulting in clinical remissions 
for a median of 90.5 d. Three further patients were enrolled 
into the study, and all seven patients received a fixed 150-mg 
s.c. dose with repeat treatment on clinical disease flare. The 
median treatment duration in the study was 26.5 mo (range 
13.5–28.5) and the median duration of clinical remission after 
each 150-mg s.c. dose was 127 d (range 55–230). Together, 
these data indicate that CAPS is solely driven by IL-1.
It appears that time until relapse is a function of the dura-
tion of IL-1 neutralization. To study this hypothesis, a math-
ematical model was developed with the aim of gaining insights 
into the production of IL-1 in vivo and to predict the time 
until disease relapse. This was possible because IL-1, which 
was undetectable in sera of patients at baseline (assay detection 
response in CAPS, demonstrating that signaling via the IL-1RI 
is crucial for the pathogenesis of CAPS (15–17). This strongly 
implies that neither IL-18 nor IL-33 plays significant roles in 
the disease, as neither of these two cytokines signals via the IL-
1RI, and suggests that the disease is caused by overproduction 
of  IL-1.  By  administering  the  human  anti–IL-1  antibody 
canakinumab to CAPS patients, we provide evidence in this 
paper that IL-1 is pivotal in the pathogenesis of CAPS. Treat-
ment with the antibody allowed the detection of IL- and the 
creation of a mathematical model, which indicates that the in 
vivo production rate of IL-1 is fivefold higher in CAPS as 
compared with healthy subjects. Furthermore, in vivo IL- 
production could be completely restored in these patients after 
canakinumab treatment.
RESULTS And dISCUSSIon
Four patients with active disease each received an i.v. dose of 
10 mg/kg canakinumab. Within 1 d, their urticarial rashes had 
disappeared, and a complete clinical response was achieved 
within 1 wk. CRP and SAA (Fig. 1 A), as well as plasma   
levels of IL-6 and IL-1Ra, returned to their normal ranges 
(Fig. 1 B), whereas levels of IL-1 and TNF- did not change 
Figure 1.  Acute phase response after treatment with canakinumab. (A–E) Data for four patients treated i.v. with 10 mg/kg canakinumab as mean  
± SEM. A, SAA and CRP; B, IL-6 and IL-1Ra; C, TNF- and IL-1; D, S100 A12 and A8/9; E, soluble IL-1RII (individual data and mean ± SEM). (F) Neutrophil 
(squares) and lymphocyte (triangle) counts for these patients for the treatment periods at 10 mg/kg i.v. (a), 1 mg/kg i.v. (b), and 150 mg s.c. (c) for treat-
ment days 1 (predose), 2 (24 h after dose), 3 (48 h after dose), and 8 (268 h after dose).JEM VOL. 206, May 11, 2009  1031
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(Emax) of IL-1 on CRP and SAA were in the region of 79 
mg/liter and 500 mg/liter, with half-maximum stimulatory 
concentrations (EC50) of 0.8 and 2 nM, respectively. The real 
values of the three independent patients were 77, 21, and 288 
mg/liter for CRP and 189, 85, and 1,060 mg/liter for SAA, 
whereas the median (25th–75th percentile) for the cohort of 
seven patients was 77 mg/liter (59–105 mg/liter) for CRP and 
377 mg/liter (189–617 mg/liter) for SAA, indicating that the 
model predicts the maximum levels of these acute phase re-
sponse parameters fairly well. Although seemingly complex, 
the model did not include the influence of membrane-bound 
or soluble IL-1 antagonists and still predicted the biological 
responses well, suggesting that natural inhibitors of the IL-1 
do not substantially contribute to neutralization of IL-1 in 
this disease. The decoy IL-1RII, which is expressed on the 
cell surface or is produced as a soluble form, binds IL-1 with 
a high-affinity dissociation constant (Kd) of 1 nM. Its binding 
affinity is further enhanced by the IL-1R accessory protein 
(AcP) (19). Serum levels of sIL-1RII in the studied CAPS pa-
tients were not different from those in healthy controls (range 
6–21 ng/ml) and did not change after treatment with cana-
kinumab (Fig. 1 E), indicating a basal, but not dynamic, con-
tribution to IL-1 inhibition. Recombinant IL-1RII has been 
shown  to  dose-dependently  compete  with  the  binding  of 
canakinumab to IL-1, which suggests that IL-1 detected as 
a complex with canakinumab does not bind sIL-1RII. Thus, 
if there is endogenously produced IL-1 bound to and neu-
tralized by the sIL-1RII, it cannot be detected by our assays. 
This makes it currently difficult to estimate the relative con-
tribution of the sIL-1RII, as compared with canakinumab, to 
neutralization of endogenously produced IL-1. The fact that 
canakinumab binds IL-1 in vitro with a Kd of 60 pM and   
its peak serum concentrations after a 150-mg s.c. dose are in 
the range of 15 µg/ml makes it likely that the vast majority of   
biological neutralization of IL-1 is mediated by canakinumab. 
However, given that there is a difference between the in vitro 
Kd and that estimated in vivo (healthy, 0.8 nM; CAPS, 0.39 
nM; Table S1) may suggest that there is competition for bind-
ing between canakinumab and the sum total of other IL-1 
binding entities in the system, whether they be soluble or 
limit <0.1 pg/ml), could be detected by an assay that mea-
sured  IL-1  complexed  with  antibody.  The  formation  of 
these complexes resulted in the extension of IL-1’s normal 
half-life of 3.5 h to that of the antibody (t1/2 30 d), thereby 
enabling the detection of IL-1 produced in vivo. Data, in-
cluding concentrations of canakinumab, complexed IL-1 
levels in blood, acute phase responses, and time until disease 
flares, were incorporated in the creation of the model (Fig. 2 A 
and supplemental text). The model included the diffusion ex-
change of canakinumab and IL-1 between the tissue and plasma 
compartments, plus elimination rates for free canakinumab, free 
IL-1, and the canakinumab–IL-1 complexes from plasma. 
Because there is a direct, although nonlinear, relationship 
through the binding reaction between antibody, free IL-1, 
and their complex, free IL-1 concentration can be calculated 
from measurement of canakinumab (Fig. 2 B) and total IL-1 
(Fig. 2 C) levels. Canakinumab rapidly suppressed free central 
and interstitial IL-1 (Fig. 2 D) to levels that were insufficient 
to stimulate downstream responses such as CRP, SAA, and 
clinical flare (Fig. 2, E–G). All these response events had similar 
kinetic profiles, which were ultimately dependent on the con-
centration of canakinumab and were well described by the 
model over multiple dosing cycles.
A posterior predictive check was performed on data from 
the three patients who had not been used in the creation of the 
model (Fig. 3 and Table S1). Although drug levels were well 
predicted (Fig. 3, A–C), IL-1 production was predicted to be 
too high for patients 5 (Fig. 3 D, dashed lines) and 7 (Fig. 3 E) 
and too low for patient 6 (Fig. 3 F). Consequently, the predic-
tions for CRP (Fig. 3, G–I), SAA (Fig. 3, J–L), and time until 
relapse (Fig. 3, M–O) were suboptimal. Correcting the model 
to fit the measured complexed IL-1 production allowed it to 
predict the remaining data correctly. Thus, the milder disease 
and longest remission time in patients 5 and 7, as well as the 
severe disease and short remission time in patient 6 (Table I), 
were entirely driven by endogenously produced IL-1. The 
slope of the IL-1 concentration–effect relationships for CRP 
and SAA were relatively shallow, with Hill coefficients of 0.8 
and 0.9, reflecting the fact that flares occurred slowly over a 
time period of 2–4 wk. The estimates of the maximum effect 
Table I.  Time until redosing in days after different doses and routes of administration of canakinumab
Patient 10 mg/kg i.v. 1 mg/kg i.v. First 150 mg 
s.c.
Second 150 mg 
s.c.
Third 150 mg 
s.c.
Fourth 150 mg 
s.c.
Fifth 150 mg 
s.c.
Sixth 150 mg 
s.c.
1 168 90 120 119 112 133 113a n.a.
2 189 91 98 133 126 132 90a n.a.
3 203 77 133 140 132 134a n.a. n.a.
4 182 98 118 141 132 127a n.a. n.a.
5 n.a. n.a. 187 156 161a n.a. n.a. n.a.
6 n.a. n.a. 91 84 98 78 55 85
7 n.a. n.a. 168 230a n.a. n.a. n.a. n.a.
Patients 1–4 were initially treated with 10 mg/kg and 1 mg/kg i.v. and subsequently with fixed doses of 150 mg s.c. Patients 5–7 did not receive i.v. dosing but received fixed 
doses of 150 mg s.c. Because of difficulties being compliant with study visit requests, patient 6 withdrew consent after the sixth dose of 150 mg canakinumab s.c. The patient 
was subsequently treated with anakinra. n.a., not applicable.
aAfter this cycle, patients were rolled over into the subsequent study, in which they were treated with a fixed dosing regimen of 150 mg s.c. every 8 wk.1032 IN VIVO IL-1 REGULATION IN CAPS | Lachmann et al.
this feedback mechanism, reducing IL-1 production to a 
normal and constitutive and, hence, IL-1–independent rate 
(Fig. 4 B). This constitutive production of IL-1 was calcu-
lated to be 6 ng/d for both diseased and healthy subjects, 
whereas CAPS patients produced an additional 25 ng/d of 
IL-1. Thus, the in vivo production of IL-1 in CAPS of   
31 ng/d is about fivefold higher than in healthy subjects and 
is IL-1 dependent. This finding is consistent with the obser-
vations that anakinra treatment decreased in vitro–produced 
IL-1 in CAPS patients (16, 21) and that baseline IL-1 mes-
senger RNA (mRNA) levels were higher in CAPS than in 
healthy subjects (Fig. 4 C). Furthermore, IL-1 mRNA ex-
pression in CAPS, but not in healthy subjects, declined within 
membrane bound, in the plasma or in the tissues. Collectively, 
the amount of IL-1 production in vivo alone appears re-
sponsible for the severity of the disease and variable duration 
of remission after administration of canakinumab treatment.
IL-1 has been shown to stimulate its own production in 
vitro (20). We looked for a similar positive-feedback loop in 
vivo by comparing the production of IL-1 in CAPS with 
healthy subjects and found that complexed IL-1 levels were 
much higher for CAPS patients over the first 8 wk after 
canakinumab treatment (Fig. 4 A); thereafter they were 
similar. This feedback mechanism was modeled by including 
a control loop whereby IL-1 stimulates its own production. 
Canakinumab, by suppressing free IL-1, appears to disrupt 
Figure 2.  Structure of the PK-biomarker-symptom model. (A) canakinumab is injected into the plasma compartment and then permeates and dis-
tributes to a peripheral (tissue) compartment, where it can bind IL-1. Unbound IL-1 in the tissue stimulates production of CRP and SAA and an in-
creased probability of a disease flare. The model was fitted to data from the first four patients for canakinumab pharmacokinetics (B), total IL-1 in 
plasma (C), and the suppression profile for free IL-1 in the peripheral (black) and central (red, dashed) compartments (D). Also fitted were data for the 
clinical response (1, flare; 0, remission; E), CRP (F), and SAA (G). Observed data for each patient are shown as colored circles. Straight lines indicate model-
derived data. Each of the four MWS patients initially received 10 mg/kg canakinumab i.v., inducing complete clinical remission. After the first relapse, they 
received 1 mg/kg i.v., followed at each subsequent relapse by 150-mg s.c. injections. Beyond the data, the model was used to predict the effect of an 8-wk 
regimen of s.c. doses of 150 mg.JEM VOL. 206, May 11, 2009  1033
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The similarities in the kinetics of S100A8/9 and IL-1 produc-
tion suggest that S100A8/9 may serve as a sensitive marker for 
subclinical inflammation in CAPS (18). Whether IL-1 stimu-
lates the production of S100A8/9 or S100A8/9 stimulates the 
production of IL-1 has not yet been fully elucidated. Al-
though IL-1 has been shown to induce S100A8/9 produc-
tion in human monocytes in vitro (22), engagement of TLR-4 
by S100A8 stimulated the production of IL-1 (23).
A simpler nonlinear mixed effect pharmacokinetic (PK) 
flare probability model was created (Table S2) to identify a 
dosing regimen that should keep IL-1 production below 
the threshold associated with clinical evidence of CAPS. This 
model established an effective inhibition constant, Ki, de-
scribing the concentration at which there is a 50:50 probabil-
ity of a flare event, and a Hill coefficient. The Hill coefficient, 
through the logit transformation, approximates the inverse of 
24 h after canakinumab treatment (Fig. 4 D) and increased at 
each relapse (Fig. 4 E and Fig. S1), paralleling the increase of 
free IL-1. This confirms that the model correctly distingui-
shed between IL-1 dependence and constitutive production 
of IL-1. Interestingly, it took 8 wk for IL-1 production to 
fully normalize in CAPS patients, despite the observed rapid 
clinical remission and normalization of CRP and SAA levels, 
suggesting that some level of inflammatory response was still 
ongoing. Although the mechanism is unclear, there was also 
complete normalization of S100A12 and S100A8/9 over a 
similar 8–10-wk period among CAPS patients who were 
treated with canakinumab, which had not occurred during 
long-term treatment with anakinra (H. Wittkowski, posters at 
The fifth International Congress on FMF and Systemic Auto-
inflammatory Diseases, Rome, 2008, and 15th Pediatric Rheu-
matology European Society Congress, London, UK, 2008). 
Figure 3.  A prediction check of the model. Simulations were performed for each of the three patients enrolled to the study who were treated only with 
150 mg canakinumab injected s.c. Predictions from the model were then compared with the observed data, taking account of their specific bodyweights. Two 
curves are presented in each case: the dashed line is the prediction check using the parameters that described the data for patients 1–4, and the solid line is 
that given by the model after adjustment to the new patient. The columns show the comparisons for each patient, with A, D, G, J, and M showing patient 5 
and so on for patients 7 and 6. The top row (A–C) compares the model prediction of canakinumab pharmacokinetics with the observed concentrations. The 
next row (D–F) shows the total captured IL-1. G–I shows CRP, J–L shows SAA, and the final row (M–O) shows the observed flare (1, flare; 0, remission) over-
laid with the model-predicted probability of flare.1034 IN VIVO IL-1 REGULATION IN CAPS | Lachmann et al.
events, patients were retreated at a mean of 69% probability 
of flare. To deduce a dose and regimen for preventing flare, 
Monte Carlo simulations were run using 1,000 replicates   
of the seven-patient database. The most practical posology 
was suggested to be 150 mg s.c. every 8 wk to keep patients 
flare free. This regimen has been applied to a randomized 
placebo-controlled study with a total of 31 patients. Data 
show that within a period of 24 wk, all patients randomized 
the variance of a Gaussian distribution of canakinumab con-
centrations over which patients transition from a remission 
to a flare state (a Hill coefficient of 4.22 is, therefore, a vari-
ance of 0.24 and a standard deviation of 0.49, such that the 
5–95% probability interval for canakinumab concentrations 
runs from 0.56 to 2.3 µg/ml, with 50:50 at 1.13 µg/ml, for 
a typical average patient). The model fitted the time of flare 
and the need for redosing very well. Across all observed 
Figure 4.  IL-1 production in CAPS patients as compared with healthy controls. (A) Total IL-1 levels in plasma for four CAPS patients (red) and 
six healthy volunteers (blue) after 10 mg/kg canakinumab i.v. (B) Model-derived estimation of IL-1 production per day in those subjects. (C) Quantitative 
mRNA expression for IL-1 in whole blood of seven patients and seven healthy subjects before canakinumab treatment. +, P = 0.0498. Horizontal lines 
indicate means of seven data points. (D) mRNA expression levels for IL-1 in four CAPS patients (left) and seven healthy volunteers (right) at baseline and 
24 h after infusion of 10 mg/kg canakinumab. +, P = 0.0144 as compared with baseline (paired Student’s t test). (E) mRNA IL-1 expression as a function 
of doses of 10 mg/kg i.v., 1 mg/kg i.v., and 150 mg s.c. shown for each cycle before dose and 24 h after dose. Note that only four CAPS patients under-
went the first two cycles, whereas data show all seven patients for the 150-mg s.c. cycle. +, first cycle, P = 0.0144; *, second cycle, P = 0.0088; **, third 
cycle, P = 0.0359 (paired Student’s t test for 24 h vs. before dose).JEM VOL. 206, May 11, 2009  1035
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Normal ranges for healthy volunteers given by the manufacturer are the fol-
lowing: IL-6, 1.5 (0.4–9.9) pg/ml; sIL-1Ra, 230 (105–1,062) pg/ml; TNF-, 
1.0 (nd–2.1) pg/ml in EDTA plasma; IL-1, <3.9 pg/ml (in serum); and 
sIL-1RII, 11 (6–21) ng/ml. S100 proteins were measured as previously de-
scribed (26). The normal upper limit of A8/9 is 450 ng/ml and of S100A12 
is 150 ng/ml in serum. CRP was measured in serum using a high-sensitivity 
automated microparticle-enhanced latex turbidimetric immunoassay (CO-
BAS MIRA; Roche). The lower limit of detection was 0.2 mg/liter with an 
interassay coefficient of variant of 4.2% at 4 mg/liter and 6.3% at 1 mg/liter. 
SAA was measured in serum by latex nephelometry (BNII autoanalyzer; 
Dade Behring). The lower limit of detection was 0.7 mg/liter, with an in-
terassay coefficient of variant of 2.6% at 15 mg/liter and 3.7% at 80 mg/liter. 
Standardization of both CRP and SAA assays is based on the respective 
World Health Organization International Reference Standards.
Mathematical models. Two mathematical models were used to analyze the 
data from the Muckle-Wells patients, full details of which are given in the 
supplemental text. In the mechanism-based model, two binding reactions 
were written for canakinumab binding IL-1, one for the plasma compart-
ment and the other for the peripheral tissue interstitium. These were repre-
sented as differential equations. Hyperbolic equations of the Hill form were 
used for CRP, SAA, absolute neutrophil count, and the probability of flare, 
parameterized with stimulation constants, Kd, and Hill coefficients. They were 
all controlled by the concentration of IL-1 in the peripheral compartment.   
A first-order rate constant ka was used to describe the absorption of drug from 
the subcutaneous injection site. PSD was the permeability–surface area coeffi-
cient for exchange of monoclonal antibody and IL-1–antibody complex be-
tween the plasma and tissue. PSL was the same for the ligand. VS and VP were 
the volumes for the systemic circulation and peripheral compartments. CLD, 
CLL, and CLDL were the clearances for drug, ligand, and drug–ligand com-
plex. RL,ind was that part of the rate of ligand input (i.e., the expression level of 
IL-1) that was independent of IL-1–stimulated positive feedback (i.e., was 
dependent on other processes). RL,dep was the rate of IL-1 input dependent 
on IL-1 receptor modulation. Kd,R was the stimulation constant for the con-
centration of free IL-1 in the peripheral compartment affecting the modula-
tor  system.  kM  was  the  turnover  rate  constant  for  the  modulator  system, 
explaining delays between changes in the driving force, IL-1, and observed 
responses. Although implemented in this model as a direct feedback of IL-1 
stimulating its own production, it is realized that there may be a chain or net-
work of interlinked responses resulting in the up-regulation of the cytokine, 
perhaps including some of those measured. However, without serial data on 
network entities, it is not possible to deduce the structure and dependencies; 
therefore, the most parsimonious model representation was chosen.
The simpler PK-flare model specified a two-compartment pharmacoki-
netic for canakinumab, linked directly to a probability function for the reoccur-
rence of disease symptoms. The probability function was a transformation of the 
statistical logistic equation into the form familiar to pharmacologists, the hyper-
bolic Hill equation. Beyond the conventional pharmacokinetic parameters, 
which are the same as those for the drug in the mechanistic binding model, the 
Hill equation specifies an inhibition constant, Ki, which is the concentration of 
canakinumab where there is a 50:50 probability of a flare occurring. The vari-
ance describing the range of canakinumab concentrations over which the flare 
probability changes from zero to one is the inverse of the Hill coefficient.
Real-time RT-PCR of IL-1. Peripheral blood samples were collected 
into PAXgene Blood RNA tubes (PreAnalytiX). Samples were stored at 
80°C until analysis. Total RNA was extracted according to the manufac-
turer’s instructions (QIAGEN). The integrity of the RNA samples was 
confirmed by 1% agarose gel electrophoresis, and the RNA concentration 
was determined spectrophotometrically. Real-time PCR was conducted 
using a 7900HT Sequence Detection System (SDS) and TaqMan assays 
(Applied Biosystems; Table I). For each measurement, an aliquot of 1 ng 
cDNA  template  was  amplified.  The  following  amplification  conditions 
were used: 50°C for 2 min, 95°C for 10 min, and then 40 cycles of 95°C 
for 15 s, followed by 60°C for 1 min each. The fluorescence signals were 
to canakinumab remained disease free, whereas 81% of pa-
tients on placebo flared (24).
In summary, a targeted medicine approach using the anti–
IL-1 antibody canakinumab in the rare monogenetic disease 
CAPS, along with data generated in healthy human subjects, 
has generated novel insights into in vivo IL-1 regulation. 
Modeling and simulation data indicated that the majority of 
elevated IL-1 in CAPS is produced by its own production 
and is completely restored after canakinumab treatment. Con-
stitutive IL-1 in healthy subjects is IL-1 independent and 
not targeted by canakinumab. Further evolution of this mech-
anism-based concept should also allow new insights into more 
heterogeneous and complex chronic inflammatory diseases.
MATERIALS AND METHODS
Patients and clinical study. Canakinumab was produced and initially charac-
terized as previously described (25). An open-label study (CACZ885A2102, an 
open-label single-center phase I/IIa dose titration study of canakinumab [IL-1 
monoclonal antibody] to assess the clinical efficacy, safety, pharmacokinetics, and 
pharmacodynamics in patients with NALP3 mutations) was conducted at the 
National  Amyloidosis  Centre  (Royal  Free  and  University  College  Medical 
School, London, UK) and approved by the local Ethic Committee and UK 
Health Authority (ClinicalTrials.gov Identifier: NCT00487708). Patients with 
proven NLRP3 mutation, clinical symptoms consistent with CAPS, and a need 
for treatment were enrolled. Patient details are given in the supplemental text. 
Canakinumab was administered as 10 mg/kg i.v. to the first four patients, and 
time until redosing after clinical relapse was recorded. At relapse, patients were 
retreated with 1 mg/kg i.v. and again monitored until the next flare became evi-
dent. From then on, patients received 150 mg canakinumab s.c. at each relapse. 
Three more patients were enrolled and were treated from the start with 150 mg 
canakinumab s.c. and redosed at each relapse. Complete remission was defined 
as absence of symptoms of skin rash, absence of joint or muscle pain, improve-
ment of arthralgia, normal serum values of CRP and SAA (<10 mg/liter), nor-
mal temperature (<37.5°C), and normal leukocyte count. Relapse or incomplete 
remission was defined as reappearance of symptoms of skin rash, reappearance of 
joint or muscle pain, reappearance of eye discomfort or redness, reappearance of 
fatigue or malaise, or reappearance of fever or chills (at least two symptoms were 
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processed using the SDS software (version 2.2). The cycle at which the fluo-
rescence from a sample crosses the threshold is called the cycle threshold 
(Ct). The measured Ct value of the IL-1 transcript (TaqMan Assay Identi-
fier Hs01555413_m1) was subtracted by the geometric mean of the Ct values 
of three reference genes, ACTG1 (TaqMan Assay Identifier Hs02340971_gH), 
GAPDH (TaqMan Assay Identifier Hs99999905_m1), and TINF2 (TaqMan 
Assay Identifier Hs00173291.m1) in the same sample to normalize between 
different samples. The samples were measured in duplicates and the averaged 
results were expressed as marker abundance normalized to the geometric 
mean of the three reference genes 2Ct.
Online supplemental material. Supplemental text shows patient histories 
and describes in detail the derivation of pharmacokinetic and pharmacody-
namic equations to build the model. Fig. S1 shows quantitative mRNA data 
for IL-1 as a function of time over 1 yr for individual patients. Table S1 
shows the parameter values for the mechanistic pharmacokinetic, biomarker, 
and clinical response model. Table S2 shows the population parameter values 
for the PK-flare model. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20082481/DC1.
This work was sponsored by Novartis, Translational Sciences (Basel, Switzerland).
The authors Philip Lowe, Sandra Daniela Felix, Christiane Rordorf, Stephan Bek, 
Nicole Hartmann, Sophie Bosset, and Thomas Jung are employees of Novartis and 
were or are involved in the preclinical or clinical development of canakinumab. The 
other authors have no conflicting financial interests.
Submitted: 3 November 2008
Accepted: 12 March 2009
REFEREnCES
  1.  Dinarello, C.A., L. Renfer, and S.M. Wolff. 1977. Human leukocytic py-
rogen: purification and development of a radioimmunoassay. Proc. Natl. 
Acad. Sci. USA. 74:4624–4627. 
  2.  Dinarello, C.A. 2002. The IL-1 family and inflammatory diseases. Clin. 
Exp. Rheumatol. 20:S1–S13.
  3.  Veltri, S., and J.W. Smith. 1996. Interleukin 1 trials in cancer patients: a 
review of the toxicity, antitumor and hematopoietic effects. Stem Cells. 
14:164–176.
  4.  Agostini, L., F. Martinon, K. Burns, M.F. McDermott, P.N. Hawkins, 
and J. Tschopp. 2004. NALP3 forms an IL-1beta-processing inflamma-
some with increased activity in Muckle-Wells autoinflammatory disorder. 
Immunity. 20:319–325. 
  5.  Dinarello,  C.A.  2004.  Unraveling  the  NALP-3/IL-1beta  inflamma-
some: a big lesson from a small mutation. Immunity. 20:243–244. 
  6.  Hoffman, H.M., J.L. Mueller, D.H. Broide, A.A. Wanderer, and R.D. 
Kolodner. 2001. Mutation of a new gene encoding a putative pyrin-like 
protein causes familial cold autoinflammatory syndrome and Muckle-
Wells syndrome. Nat. Genet. 29:301–305. 
  7.  Aksentijevich, I., M. Nowak, M. Mallah, J.J. Chae, W.T. Watford, S.R. 
Hofmann, L. Stein, R. Russo, D. Goldsmith, P. Dent, et al. 2002. De 
novo CIAS1 mutations, cytokine activation, and evidence for genetic 
heterogeneity in patients with neonatal-onset multisystem inflammatory 
disease (NOMID): a new member of the expanding family of pyrin-as-
sociated autoinflammatory diseases. Arthritis Rheum. 46:3340–3348. 
  8.  Aksentijevich, I., D. Putnam, E.F. Remmers, J.L. Mueller, J. Le, R.D. 
Kolodner, Z. Moak, M. Chuang, F. Austin, R. Goldbach-Mansky, et al. 
2007. The clinical continuum of cryopyrinopathies: novel CIAS1 muta-
tions in North American patients and a new cryopyrin model. Arthritis 
Rheum. 56:1273–1285. 
  9.  Hull, K.M., N. Shoham, J.J. Chae, I. Aksentijevich, and D.L. Kastner. 
2003. The expanding spectrum of systemic autoinflammatory disorders 
and their rheumatic manifestations. Curr. Opin. Rheumatol. 15:61–69. 
  10.  Aganna, E., F. Martinon, P.N. Hawkins, J.B. Ross, D.C. Swan, D.R. 
Booth, H.J. Lachmann, A. Bybee, R. Gaudet, P. Woo, et al. 2002. 
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a 
broad phenotype including recurrent fever, cold sensitivity, sensorineu-
ral deafness, and AA amyloidosis. Arthritis Rheum. 46:2445–2452. 